Novartis’ Sandoz subsidiary has taken its first steps into the emerging market for medical cannabis products, signing a global supply deal with Canadian producer Tilray.
A second mobile app developed by Pear Therapeutics to help opioid use disorder patients who have a more successful response to therapy has been given a green light by the FDA.
Novartis’ generics and biosimilars arm, Sandoz, has confirmed it is to launch its biosimilar of AbbVie’s Humira (adalimumab) in Europe this year after the two companies settled intellectual
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.